Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin (TTP399), an adjunct therapy to insulin.
Life with T1D: 19 Things I’ve Learned in 19+ Years
A guest post from Breakthrough T1D's social media manager, Grace Bennett, about life-with-T1D lessons she's learned in 19+ years.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Dexcom G7 Continuous Glucose Monitor Cleared by the FDA
Dexcom G7® Continuous Glucose Monitor system was cleared by the FDA, giving people with diabetes more options for managing their blood-sugar levels.
The Innovative Insulin Your Kids Can’t Use…Yet
What if it was safe and effective to take a rapid-acting inhaled insulin in children/teens as they start eating? The INHALE-1 clinical trial is finding out.
Glucagon: Your Friend in Low Places
Glucagon. It’s a word familiar to people with T1D, yet one most hope to avoid discussing. But what is glucagon and what is its role in the management of T1D?
100, 100: Breakthrough T1D Research Leads to a New Class of Glucose-Lowering Agents
You’ve seen the ads: Victoza®. Ozempic®. Trulicity®. But did you know that these drugs came about, in part, because of type 1 diabetes research?
100, 100: Genetically Engineered Human Insulin Created
In 1976, researchers set out to synthesize the human insulin gene and make human insulin, and Breakthrough T1D researchers had multiple hands in the biosynthesis of it.
Insulin Affordability? Yes, Please: Breakthrough T1D Joins Civica to Make Low-Cost Insulin Available to All Americans
In conjunction with leading partners, Breakthrough T1D lends its support to Civica, to help combat a nationwide insulin affordability crisis.
